Palisade Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Palisade Capital Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-3,927	Closed	-$38K	–	457
2017 Q2	$38K	Buy	3,927 +241	+7%	+$4.92K	﹤0.01%	431
2017 Q1	$89K	Buy	3,686 +508	+16%	+$12.7K	﹤0.01%	426
2016 Q4	$102K	Buy	3,178 +763	+32%	+$32.5K	﹤0.01%	453
2016 Q3	$121K	Buy	2,415 +627	+35%	+$26K	﹤0.01%	553
2016 Q2	$76K	Buy	1,788 +517	+41%	+$28.2K	﹤0.01%	524
2016 Q1	$84K	Hold	1,271	–	–	﹤0.01%	525
2015 Q4	$79K	Buy	+1,271	New	+$89.4K	﹤0.01%	519

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Palisade Capital Management's MACK Position: Q3 2017 in Review

Palisade Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 3,927 shares — an estimated $38K sold.

Palisade Capital Management first reported a position in MACK in Q4 2015 and held it in 7 quarters. The position peaked at $121K in Q3 2016. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

Palisade Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Palisade Capital Management sold 3,927 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $38K.
Palisade Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2015 and held it in 7 quarters.
Palisade Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $121K in Q3 2016.
73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Palisade Capital Management's 13F filing for Q3 2017, filed 31 Oct 2017.